BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Limertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Limertinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05306132-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Limertinib: Phase 1 readout est. (NCT05306132)
DESCRIPTION:Limertinib\, phase 1.\nStudy: Study to Assess the Safety\, Tole
 rability\, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202
  With or Without ASK120067\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/limertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05306132
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982924-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Limertinib: Phase 2 readout est. (NCT06982924)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study on the Efficacy and Safety of the Combination of Limertinib a
 nd Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06982924
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612137-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Limertinib: Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Limertinib\, phase 1/2.\nStudy: Study of IBI3005 Combination Th
 erapy in Participants With Unresectable\, Locally Advanced or Metastatic S
 olid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Limertinib: Phase 3 readout est. (NCT07109531)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatme
 nt of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpr
 ession After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07109531
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Limertinib: Phase 2 readout est. (NCT07038460)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Phase II Randomized Trial of Limertinib Followed by Sintilimab a
 nd Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as 
 Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001995-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Limertinib: Phase 2 readout est. (NCT07001995)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lime
 rtinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Tran
 sformation After EGFR-TKI Progression\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7001995
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413952-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Limertinib: Phase 2 readout est. (NCT07413952)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lime
 rtinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07413952
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-7622@assetmemo.bio
DTSTAMP:20261121T005814Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Limertinib: Phase 3 readout est. (NCT07897188)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET
 + Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 30 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limerti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07897188
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
